Zoetis Inc. $ZTS Shares Sold by Banque Transatlantique SA

Key Points

• Banque Transatlantique SA sold 130,806 shares of Zoetis Inc., reducing its holdings by 27% to 354,317 shares.
• Zoetis reported a quarterly earnings per share (EPS) of $1.76, exceeding analyst expectations of $1.62, with revenue reaching $2.46 billion.
• Several institutional investors increased their holdings in Zoetis, with Vanguard Group owning over 41 million shares valued at approximately $6.84 billion.

Banque Transatlantique SA lowered its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 27.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 354,317 shares of the company's stock after selling 130,806 shares during the quarter. Zoetis makes up about 1.0% of Banque Transatlantique SA's holdings, making the stock its 18th largest holding. Banque Transatlantique SA owned 0.08% of Zoetis worth $53,912,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Brighton Jones LLC increased its holdings in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after purchasing an additional 2,978 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of Zoetis during the fourth quarter worth $308,000. Aptus Capital Advisors LLC boosted its position in shares of Zoetis by 46.6% during the fourth quarter. Aptus Capital Advisors LLC now owns 6,643 shares of the company's stock worth $1,082,000 after buying an additional 2,111 shares during the period. Captrust Financial Advisors boosted its holdings in Zoetis by 23.0% in the fourth quarter. Captrust Financial Advisors now owns 98,701 shares of the company's stock valued at $16,081,000 after purchasing an additional 18,476 shares during the period. Finally, Bridgefront Capital LLC purchased a new position in Zoetis in the fourth quarter valued at $785,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $202.43.

Zoetis Trading Down 0.0%

ZTS traded down $0.05 during trading on Friday, hitting $153.15. The company's stock had a trading volume of 1,895,936 shares, compared to its average volume of 2,304,532. The firm's 50 day moving average price is $153.16 and its 200-day moving average price is $157.72. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The stock has a market cap of $67.87 billion, a PE ratio of 26.36, a PEG ratio of 2.46 and a beta of 0.89. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis's revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.